Zh
Zhejiang Jiuzi
Hangzhou CNFounded 202150 employees
Private CapbiotechPrivateOncology
Platform: EV Biotech
Market Cap
N/A
All Drugs
4
Clinical Trials
10
Failed / Terminated
0
FDA Approved
1
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| ZHE-6042 | ZHE-6042 | Phase 2 | 2 | FXIa | PBCAS | ||
| ZHE-9252 | ZHE-9252 | Phase 3 | 3 | FLT3 | Bladder Ca | ||
| ZHE-740 | ZHE-740 | Approved | 3 | JAK2 | PBCOCD | ||
| Kemalucimab | ZHE-6646 | Phase 2/3 | 2 | CD47 | MCCCrohn's |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (8)